Your Advantages of Stem Cell Preservation

Storage of your cells from the skin and the stem cells contained therein as preventive measure on the highest level and in accordance with the latest scientific and technologic developments will be as self-evident as vaccination is today.

Prevention can hardly be any more intelligent!


Advantages of Preservation

  • Biological life insurance as preventive health care
  • Back-up copy of your young and healthy stem cells, as our genes are continuously exposed to environmental influences (viral infections, energetic radiation of earth and sun, environmental pollutants) that may cause considerable changes of the cells
  • Create your spare parts store, as stem cells dispose of a renewal and repair function and replace defective cells
  • Manifold treatment possibilities, in which stem cells even today are of high significance and will play an even bigger role in the future

TICEBA Offers Security

  • TICEBA is a company founded and lead by physicians and therefore disposes of the necessary know-how with regard to the handling of stem cells.
  • TICEBA is the only company worldwide disposing of the exclusive license of the patent from Brigham and Women's Hospital, university hospital of the Harvard Medical School in Boston/USA, entitling them to determine and isolate the valuable ABCB5+ stem cells.
  • At TICEBA, everything is in one hand: Thanks to our own cell biological laboratory and our own cryo-equipment, no cell transport is necessary.
  • TICEBA takes a part in several research projects and thereby supports the research of the particularly important ABCB5+ stem cells in order to be able to offer new areas of application and new chances in the future.
News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter